BR112016028083A2 - Composição oral farmacêutica de isotretinoina e seu processo de preparação - Google Patents

Composição oral farmacêutica de isotretinoina e seu processo de preparação

Info

Publication number
BR112016028083A2
BR112016028083A2 BR112016028083A BR112016028083A BR112016028083A2 BR 112016028083 A2 BR112016028083 A2 BR 112016028083A2 BR 112016028083 A BR112016028083 A BR 112016028083A BR 112016028083 A BR112016028083 A BR 112016028083A BR 112016028083 A2 BR112016028083 A2 BR 112016028083A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
isotretinoin
oral pharmaceutical
preparation process
present
Prior art date
Application number
BR112016028083A
Other languages
English (en)
Inventor
Rao Rajesh
Kumar Fanda Anuj
Kumar Jain Satish
Barat Singh Romi
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR112016028083A2 publication Critical patent/BR112016028083A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÃO ORAL FARMACÊUTICA DE ISOTRETINOINA,SEU PROCESSO DE PREPARAÇÃO E SEU USO. A presente invenção provê uma composição oral farmacêutica de isotretinoína apresentando biodisponibilidade melhorada. A presente invenção também relaciona um processo para preparar a composição oral farmacêutica da presente invenção.
BR112016028083A 2014-05-29 2015-05-29 Composição oral farmacêutica de isotretinoina e seu processo de preparação BR112016028083A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1422DE2014 2014-05-29
IN1736DE2014 2014-06-30
IN3488DE2014 2014-12-01
PCT/IB2015/054087 WO2015181802A2 (en) 2014-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin

Publications (1)

Publication Number Publication Date
BR112016028083A2 true BR112016028083A2 (pt) 2017-08-22

Family

ID=54699996

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028083A BR112016028083A2 (pt) 2014-05-29 2015-05-29 Composição oral farmacêutica de isotretinoina e seu processo de preparação

Country Status (10)

Country Link
US (2) US9999606B2 (pt)
EP (1) EP3148644A4 (pt)
JP (1) JP2017516792A (pt)
AU (1) AU2015265454A1 (pt)
BR (1) BR112016028083A2 (pt)
CA (1) CA2950531A1 (pt)
MA (1) MA40312A (pt)
MX (1) MX2016015465A (pt)
RU (1) RU2016150863A (pt)
WO (1) WO2015181802A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956831A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne
CN111032017A (zh) 2017-06-29 2020-04-17 地平线生物科学有限责任公司 异维a酸口腔粘膜制剂及其使用方法
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1318791E (pt) * 2000-09-22 2004-11-30 Galephar M F Composicao farmaceutica semi-solida de isotretinoina
JP4061015B2 (ja) * 2000-10-30 2008-03-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 レチノイン酸レセプターアゴニスト作用を有する薬剤含有組成物
EA200400782A1 (ru) * 2001-12-06 2005-08-25 Рэнбакси Лабораториз Лимитед Композиция изотретиноина с измельчением компонентов до степени наночастиц
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
CN1943567A (zh) * 2006-10-12 2007-04-11 华东理工大学 维a酸类药物的自微乳化组合物及其制备方法
CN102802729A (zh) * 2009-05-20 2012-11-28 兰贝克赛实验室有限公司 异维a酸的液体剂型
US10028972B2 (en) * 2010-10-21 2018-07-24 Cadila Healthcare Limited Pharmaceutical compositions of anti-acne agents
US9078925B2 (en) * 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
CN105682646A (zh) * 2013-06-04 2016-06-15 南达科他州立大学 用于口服药物递送的新型核-壳纳米颗粒

Also Published As

Publication number Publication date
AU2015265454A1 (en) 2016-12-15
MA40312A (fr) 2017-04-05
WO2015181802A3 (en) 2016-03-03
WO2015181802A2 (en) 2015-12-03
JP2017516792A (ja) 2017-06-22
RU2016150863A3 (pt) 2018-12-29
RU2016150863A (ru) 2018-07-03
CA2950531A1 (en) 2015-12-03
US9999606B2 (en) 2018-06-19
US20160089353A1 (en) 2016-03-31
US20180193299A1 (en) 2018-07-12
EP3148644A2 (en) 2017-04-05
MX2016015465A (es) 2017-03-27
EP3148644A4 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
BR112016020112A2 (pt) anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica
BR112018010102A2 (pt) conjugados farmacêuticos de anticorpos sítio-específicos para her2
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112015025814A2 (pt) composição farmacêutica para uso inalatório, processo para a preparação de uma composição farmacêutica, composição sólida para uso como um diluente de pós para inalação e kit para a administração de um fármaco como pó para inalação
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
BR112017025427A2 (pt) composição farmacêutica oral
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
IN2014CH00840A (pt)
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
EP3302438A4 (en) ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN
BR112019002729A2 (pt) composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
BR112016026684A2 (pt) Fertilizante à base de enxofre
BR112016028698A2 (pt) preparação de piperidina-4-carbotioamida
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
BR112017025793A2 (pt) composição de preparação sólida contendo pranlucaste com biodisponibilidade melhorada e método para preparar a mesma
BR112016026814A2 (pt) 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.